Global Colorectal Cancer (CRC) Drugs Market, Forecast Till 2025

  • Category : Healthcare and Pharma
  • |
  • ID : 794902
  • |
  • Publishe Date : February 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Colorectal Cancer (CRC) Drugs Market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. Increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.

Aging population and rising awareness about this disease are major driving factors. Government initiatives to provide better and more affordable Drug classs as well as favorable reimbursement policies are expected to fuel industry growth.

Factors, such as high cost of Drug class may hinder the growth of the overall market.

Lack of pipeline agents in this setting presents a good opportunity for development of effective Drug classs that can improve cure rates for resected patients.

On the basis of drug class, the market is segmented into Chemotherapy, Immunotherapy. Immunotherapy dominated the market based on drug class in 2016, owing to increasing adoption of targeted therapies such as Avastin and Erbitux.

On the basis of End-user, the Colorectal Cancer (CRC) Drugs market is divided into hospitals, clinics, research institute, among others.

Regionally U.S. accounted for the largest share based on country and is projected to maintain its dominance through to 2022 owing to growing disease burden, increasing Drug class rate, and high cost of drugs.

Some of the key players operating in this market include Amgen, Bayer, Bristol-Myers Squibb, Eli Lilly, Merck, Roche, and Sanofi.

Key Benefits of the Report:
* Global, Regional, Country, Drug class, and Route of End-user Market Size and Forecast from 2014-2025
* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies
* Identification of key companies that can influence this market on a global and regional scale
* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies
* Detailed insights on emerging regions, Drug class& End-user, and competitive landscape with qualitative and quantitative information and facts

Target Audience:
* Colorectal Cancer (CRC) Drugs providers
* Traders, Importer and Exporter
* Raw material suppliers and distributors
* Research and consulting firms
* Government and research organizations
* Associations and industry bodies

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics , capacity End-user, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:
* Original Manufacturer,
* Drug class Supplier,
* Distributors,
* Government Body & Associations, and
* Research Institute
* Pharmacies

TABLE OF CONTENT

1 EXECUTIVE SUMMARY

2 METHODOLOGY AND MARKET SCOPE
2.1 Research Methodology
2.2 Research Scope & Assumptions

3 COLORECTAL CANCER (CRC) DRUGS MARKET — INDUSTRY OUTLOOK
3.1 Market Segmentation and Scope
3.2 Market Size & Growth Prospects
3.3 Colorectal Cancer (CRC) Drugs Market — Value Chain / Supply Chain Analysis
3.3.1 Company Landscape
3.4 Colorectal Cancer (CRC) Drugs Market — Market Dynamics
3.4.1 Market Driver
3.4.2 Market Restraints
3.4.3 Market Challenges
3.5 Colorectal Cancer (CRC) Drugs Market Company Market Share, 2017
3.6 Colorectal Cancer (CRC) Drugs Market — Porter\'s Five Forces Analysis
3.7 Colorectal Cancer (CRC) Drugs Market — Pestel Analysis

4 COLORECTAL CANCER (CRC) DRUGS MARKET DRUG CLASS OUTLOOK
4.1 Colorectal Cancer (CRC) Drugs Market Share by Drug class, 2016 & 2025
4.2 Immunotherpay
4.4 Chemotherapy

5 COLORECTAL CANCER (CRC) DRUGS MARKET END-USER OUTLOOK
5.1 Colorectal Cancer (CRC) Drugs Market Share by End-user, 2016 & 2025
5.2 Hospitals
5.3 Clinics
5.4 Pharmacies
5.5 Research and institute

6 COLORECTAL CANCER (CRC) DRUGS MARKET REGIONAL OUTLOOK
6.1 Colorectal Cancer (CRC) Drugs Market Share by Region, 2016 & 2025
6.2 North America
6.2.1 North America Colorectal Cancer (CRC) Drugs Market, 2014 - 2025
6.2.2 North America Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.2.3 North America Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.2.5 U.S.
6.2.5.1 U.S. Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.2.5.2 U.S. Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.2.6 Canada
6.2.6.1 Canada Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.2.6.2 Canada Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.3 Europe
6.3.1 Europe Colorectal Cancer (CRC) Drugs Market, 2014 - 2025
6.3.2 Europe Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.3.3 Europe Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.3.5 Germany
6.3.5.1 Germany Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.3.5.2 Germany Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.3.6 UK
6.3.6.1 UK Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.3.6.2 UK Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.4 Asia Pacific
6.4.1 Asia Pacific Colorectal Cancer (CRC) Drugs Market, 2014 - 2025
6.4.2 Asia Pacific Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.4.3 Asia Pacific Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.4.5 Australia
6.4.5.1 Australia Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.4.5.2 Australia Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.4.6 New Zealand
6.4.6.1 New Zealand Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 -
2025
6.4.6.2 New Zealand Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 -2025
6.4.7 China
6.4.7.1 China Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.4.7.2 China Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.4.8 India
6.4.8.1 India Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.4.8.2 India Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.4.9 Japan
6.4.9.1 Japan Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.4.9.2 Japan Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.5 South America
6.5.1 South America Colorectal Cancer (CRC) Drugs Market, 2014 - 2025
6.5.2 South America Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.5.3 South America Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.5.5 Brazil
6.5.5.1 Brazil Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.5.5.2 Brazil Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.5.6 Mexico
6.5.6.1 Mexico Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.5.6.2 Mexico Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025
6.6 MEA
6.6.1 MEA Colorectal Cancer (CRC) Drugs Market, 2014 - 2025
6.6.2 MEA Colorectal Cancer (CRC) Drugs Market, By Drug class, 2014 - 2025
6.6.3 MEA Colorectal Cancer (CRC) Drugs Market, By End-user, 2014 - 2025

7 COMPETITIVE LANDSCAPE
7.1 Amgen
7.1.2 Financial performance
7.1.3 Drug class benchmarking
7.1.4 Strategic initiatives
7.2 Bayer
7.2.1 Company overview
7.2.2 Financial performance
7.2.3 Drug class benchmarking
7.2.4 Strategic initiatives
7.3 Bristol-Myers Squibb
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Drug class benchmarking
7.3.4 Strategic initiatives
7.4 Eli Lilly
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Drug class benchmarking
7.4.4 Strategic initiatives
7.5 Merck
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Drug class benchmarking
7.5.4 Strategic initiatives
7.6 Roche
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Drug class benchmarking
7.6.4 Strategic initiatives
7.7 Sanofi
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Drug class benchmarking
7.7.4 Strategic initiatives

End of the report
Disclaimer.

Content are not available

Choose License Type